688739 成大生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.3134.8417.51513.25124.350
总资产报酬率 ROA (%)2.2014.6287.19512.50822.357
投入资产回报率 ROIC (%)2.3064.8267.49013.19822.112

边际利润分析
销售毛利率 (%)82.82183.65087.11489.85186.253
营业利润率 (%)31.08033.01546.24648.97954.274
息税前利润/营业总收入 (%)27.81128.80042.97249.20153.120
净利润/营业总收入 (%)25.00526.62339.34042.74346.011

收益指标分析
经营活动净收益/利润总额(%)108.304112.11097.58698.59691.800
价值变动净收益/利润总额(%)-0.9965.7473.2521.3788.393
营业外收支净额/利润总额(%)-0.576-0.246-0.1540.803-1.897

偿债能力分析
流动比率 (X)18.49320.31728.22826.98013.324
速动比率 (X)17.34319.13326.47125.64712.092
资产负债率 (%)4.8974.7834.0394.5008.043
带息债务/全部投入资本 (%)-0.900-0.976-1.100-1.205--
股东权益/带息债务 (%)-11,087.358-10,216.152-9,068.384-8,265.151-3,562.374
股东权益/负债合计 (%)1,942.2371,990.5712,375.7822,122.0051,143.383
利息保障倍数 (X)-8.998-6.967-13.415-282.688-368.722

营运能力分析
应收账款周转天数 (天)232.598225.605205.242126.6440.000
存货周转天数 (天)510.460567.585665.725566.5380.000